TAST - SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FUSN DRQ KAMN TAST | Benzinga
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)'s sale to AstraZeneca. Under the terms of the proposed transaction, AstraZeneca would acquire all of Fusion's outstanding shares for $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone. If you are a Fusion shareholder, click here to learn more about your rights and options.
Dril-Quip, Inc. (NYSE:DRQ)'s merger with Innovex Downhole ...